Trial Profile
Agressiveness and agitation of acute psychotic patients: influence in safety and effectiveness of risperidone treatment.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 Sep 2012
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- Sponsors Janssen-Cilag
- 10 Mar 2011 Actual initiation date (Nov 2001) added as reported by ClinicalTrials.gov.
- 10 Mar 2011 Actual end date (August 2002) added as reported by ClinicalTrials.gov.
- 13 Jan 2010 Planned number of patients changed from 1250 to 1882 as reported by ClinicalTrials.gov.